08:00 | Registration |
| Session Chair: Charles Cox, Head Genetics Experiment Design and Delivery, GSK Pharmaceuticals |
| |
09:00 | Shaping Personalized Medicine through Partnerships Cecilia Schott, Head Personalized Healthcare, Corporate Business Development Global Product & Portfolio Strategy, AstraZeneca, United States of America
The deeper understanding of the molecular mechanisms of diseases creates an intrinsic need for diagnostic tools that can predict a patient response to a drug treatment. As a result the reality of drug development is no longer a well known and established process followed by biopharmaceutical companies. The increasing speed of technology innovation associated with biomarker discovery is shaping drug development and creating new business models. When a diagnostic is co-developed with a drug to guide its therapy, the aim is that the drug and diagnostic will be incorporated in clinical practice at the same time. Biopharmaceutical companies need simultaneous access to a variety of selection tools that are not part of their core capabilities and can only be made available through partnerships. Bringing together two industries, biopharmaceutical and diagnostics, which have very different business strategies, requires flexibility and creativity to deliver better patient outcomes. |
09:45 | | Keynote Presentation Personalised Breast Cancer Medicine Carlos Caldas, Group Leader, Cancer Research UK, Cambridge Institute, United Kingdom
|
|
10:45 | Coffee and Networking |
11:15 | Blood-based Biomarker Assays for Personalised Tumour Therapy Thomas Krahn, Head of Global Biomarker Research Department, Bayer Pharma Ag, Germany
Blood based biomarker for early diagnosis and patient stratification, detection of circulating tumour DNA in cancer patients and Isolation and molecular analysis of circulating tumour cells will be discussed in the presentation. |
12:00 | Clinical Implications of Intratumoral Heterogeneity in High Grade Serious Ovarian Cancer James Brenton, Senior Group Leader, Cancer Research UK, United Kingdom
|
12:45 | Lunch and Networking |
| Session Chair: Iain Miller, European Personalized Medicine Association |
| |
14:15 | |
15:15 | Strategy of Sequencing the Whole Genome in Clinical Practice with Illumina X Ten Jurgen Eils, Head, German Cancer Research Centre, Germany
Resources and infra-structure required for playing the leading role in clinical sequencing will be highlighted in this presentation. Furthermore the aspects of precision oncology and the relating IT challenges will be discussed. |
16:00 | Coffee and Networking |
16:30 | Pathway Illumination for Disease Research - Psychiatric Disorders and Antidepressant Treatment Response Christoph Turck, Head, Max Planck Institute of Psychiatry, Germany
Biomarkers predicting a priori whether an individual patient will respond to the treatment of choice and an early distinction of responders and non-responders during antidepressant therapy can have a significant impact for realizing strategic treatment. |
17:15 | End of Day One |